AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8850249
Drug: UVB irradiation
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: UVB irradiation (4 times the minimal erythema dose)
Trial: 2163421
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once a day
Trial: 25981908
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy delivered through a face mask
Trial: 24180712
Drug: Levosimendan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (12 µg/kg bolus over 15 minutes, followed by 0.2 µg/kg/min infusion for 24 hours)
Trial: 24180712
Drug: Dobutamine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (7.5 µg/kg/min infusion for 24 hours)
Trial: 10775816
Drug: Pre‐emptive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive therapy with ganciclovir
Trial: 9185458
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard lidocaine infusion)
Trial: 3948546
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen therapy to raise PaO2 ≥ 60 mm Hg (group 1, n = 6)
Trial: 3948546
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen therapy to raise PvO2 ≥ 36 mm Hg (group 2, n = 6)
Trial: 28295425
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of atropine administered before deflation of the cryoballoon (trial group)
Trial: 28295425
Drug: Atropine administered
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine administered after the onset of hemodynamic variation (control group)
Trial: 28295425
Drug: Prophylactic atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic atropine administration
Trial: 25201758
Drug: Active group
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active group (patients chose route of administration)
Trial: 25201758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (physician decided route of administration)
Trial: 25201758
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sublingual immunotherapy)
Trial: 8067760
Drug: LY217896 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY217896 (75 mg) once daily for 7 days
Trial: 28320223
Drug: Valbenazine 40
RxNorm normalized name: valbenazine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 40 mg/day
Trial: 28320223
Drug: Valbenazine 80
RxNorm normalized name: valbenazine 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine 80 mg/day
Trial: 19847073
Drug: Memory training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memory training (e.g. memory skills training, imagery, method of loci)
Trial: 9890849
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide gas at graded concentrations (n = 8)
Trial: 9890849
Drug: Intravenous isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous isosorbide dinitrate, 2.5 mg (n = 8)
Trial: 28301690
Drug: ATG-10 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-10 (10 mg/kg)
Trial: 28301690
Drug: ATG-6 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-6 (6 mg/kg)
Trial: 18663579
Drug: Hypodermic needle
RxNorm normalized name: Hypodermic Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypodermic needle (25‐G)
Trial: 16551310
Drug: Increased fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased fluid intake by 1.5 L of water
Trial: 16551310
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication (8 mL inactive syrup per day)
Trial: 15621108
Drug: Triple dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dosing of basiliximab (3 doses: prior to transplantation, day 4, and day 21)
Trial: 15621108
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of basiliximab (prior to transplantation and day 4)
Trial: 10752804
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) 25 mg and glucose 5 g administered simultaneously
Trial: 8883420
Drug: STn linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, with low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Trial: 8883420
Drug: STn linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STn linked to KLH with DETOX-B adjuvant, 100 micrograms, subcutaneous injection at weeks 0, 2, 5, and 9, without low-dose cyclophosphamide (CTX, 300 mg m-2) pretreatment.
Trial: 6374537
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg per day
Trial: 6374537
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 1.25 mg per day
Trial: 6374537
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens <0.625 mg per day
Trial: 29471904
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) for 6 months with pyridoxine
Trial: 19128642
Drug: Betahistine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (24 mg/d for 1 month)
Trial: 19128642
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between exercise and medication groups
Trial: 15871016
Drug: (131)I plus
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (131)I plus lithium (group I+L)
Trial: 12836801
Drug: Educational Treatment
RxNorm normalized name: OneTouch Ultra Mini Educational Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational Treatment (ET)
Trial: 8881455
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with low serum TSH (< 0.4 mU/l) (n = 44)
Trial: 8881455
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with TSH > 4.0 mU/l (n = 44)
Trial: 1810019
Drug: Naproxen 1000
RxNorm normalized name: naproxen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 1000 mg daily for 4 days
Trial: 17825130
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg/day for Week 1 followed by 20 mg/day thereafter)
Trial: 15741841
Drug: 1.2 g.min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g.min of maltodextrin + 0.6 g.min of fructose (MD+F)
Trial: 15741841
Drug: 1.8 g.min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g.min of maltodextrin (MD)
Trial: 11316178
Drug: Antibiotics (norfloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (norfloxacin and neomycin)
Trial: 9390597
Drug: Thiopental 4
RxNorm normalized name: thiopental 400 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 4 mg/kg
Trial: 9141939
Drug: Ketamine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.5 mg/kg
Trial: 30729953
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion at 3 μg/kg/h, halved after arterial anastomosis and continued for 3 days
Trial: 30729953
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no terlipressin infusion)
Trial: 23471131
Drug: 900‐mg phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900‐mg phosphate diet plus lanthanum carbonate (LC)
Trial: 23471131
Drug: 900‐mg phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900‐mg phosphate diet
Trial: 21455083
Drug: Haptic rendering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haptic rendering of bone surface, skin pop, dura pop, and subcutaneous tissue.
Trial: 15028362
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) switched on
Trial: 9093988
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g CPP
Trial: 9093988
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g CPP
Trial: 9093988
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g CPP
Trial: 9093988
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g CPP (whole-grain cereal)
Trial: 9093988
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g CPP (whole-grain cereal)
Trial: 9093988
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g CPP (whole-grain cereal)
Trial: 2834938
Drug: Enalaprilat (intravenous)
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalaprilat (intravenous)
Trial: 29381802
Drug: Glucose-containing beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 22°C
Trial: 29381802
Drug: Glucose-containing beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-containing beverage (75 g glucose dissolved in 300 mL water) at 0°C
Trial: 26065720
Drug: CPAP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP plus conservative care (CC) for 3 months
Trial: 19902277
Drug: Conservative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative care (CC)
Trial: 19195513
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + atorvastatin 20 mg
Trial: 19195513
Drug: ABT-335 +
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 + atorvastatin 40 mg
Trial: 11349176
Drug: Ampicillin and
RxNorm normalized name: Ampicillin and sulbactam only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin and Penicillin G
Trial: 326052
Drug: Acetazolamide (Diamox)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (Diamox) administered to 24 eyes
Trial: 25403306
Drug: Mexidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (1 tablet (125 mg) 3 times a day for 3 weeks) along with standard treatment
Trial: 20813517
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 50 μg
Trial: 20813517
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with morphine 100 μg
Trial: 20813517
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 1.25mg and sufentanil 5 μg with saline placebo
Trial: 15833887
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 125 microg twice daily for 3 weeks and once daily for a fourth week (dosage doubled for infants > or =1200 g)
Trial: 11981357
Drug: 2 NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 NRTIs + 1 protease inhibitor (stavudine + lamivudine + indinavir)
Trial: 11981357
Drug: 2 NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 NRTIs + 1 nonnucleoside reverse transcriptase inhibitor (stavudine + didanosine + nevirapine)
Trial: 8918498
Drug: Weight-based doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based doses of CAF regimen (cyclophosphamide, doxorubicin, and fluorouracil)
Trial: 6760379
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg trimipramine at bedtime for 4 weeks
Trial: 28371461
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine + insulin glargine 300 U/mL (G + G300)
Trial: 28371461
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro + insulin glargine biosimilar (L + GB)
Trial: 11472279
Drug: Music in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music in combination with therapeutic suggestions
Trial: 9720727
Drug: Zidovudine and
RxNorm normalized name: zidovudine and lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine and alpha-interferon (proposed treatment)
Trial: 2805034
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 120 mg daily
Trial: 961472
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) administered as a single oral dose with food
Trial: 961472
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) administered as a single oral dose in fasting state
Trial: 26018048
Drug: MISSION‐Vet Implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MISSION‐Vet Implementation as Usual (IU) - standard training and access to the MISSION‐Vet treatment manuals
Trial: 11185998
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) at 1 to 2 g/kg
Trial: 11185998
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral prednisolone (o‐PSL) (2 mg/kg for 2 weeks)
Trial: 11185998
Drug: Parenteral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral methylprednisolone (mPSL) (5 mg/kg for 5 days)
Trial: 11185998
Drug: Pulsed parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed parenteral methylprednisolone (PmPSL) (30 mg/kg for 3 days)
Trial: 8349375
Drug: gallopamil, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil, 150 mg/day
Trial: 8349375
Drug: nifedipine, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine, 30 mg/day
Trial: 3304725
Drug: Danazol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (50 to 600 mg daily for 6 months)
Trial: 24878174
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular hypotensive medications
Trial: 20175241
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 mu g/kg iv administered over 5 min)
Trial: 17272962
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d quinapril plus 5 mg/d amlodipine besylate
Trial: 17272962
Drug: 40 mg/d
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/d quinapril
Trial: 7843751
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg losartan and 20 mg enalapril
Trial: 28639937
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone plus 2 g/kg of IVIG in divided doses within 5 days of the first commencement of steroid therapy
Trial: 26315981
Drug: Extended-release guanfacine
RxNorm normalized name: guanfacine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release guanfacine (N=30)
Trial: 21289620
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Sativex (5.4 mg THC, 5.0 mg CBD)
Trial: 21289620
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Sativex (16.2 mg THC, 15.0 mg CBD)
Trial: 22027622
Drug: Erythropoietin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (500 IU/kg) and iron sucrose (200 mg)
Trial: 19429471
Drug: Mirtazapine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (30 mg oral dose)
Trial: 9278211
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg daily for 21 days) + Warfarin (25 mg single dose)
Trial: 8338265
Drug: 1% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% dextrose in lactated Ringer's solution (RLG1)
Trial: 8338265
Drug: 0.9% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% dextrose in lactated Ringer's solution (B66)
Trial: 3495027
Drug: TMP‐SMZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP‐SMZ (50 mg/kg daily)
Trial: 3495027
Drug: TMP‐SMZ (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP‐SMZ (normal G‐6‐PD)
Trial: 3495027
Drug: Vancomycin (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (normal G‐6‐PD)
Trial: 29052439
Drug: Dual peroxisome
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual peroxisome proliferator-activated receptor agonist aleglitazar
Trial: 27160738
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment (motor learning-based treatment)
Trial: 27160738
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment if needed after the study)
Trial: 22951500
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg/d orally for 14 days quarterly)
Trial: 22105813
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/d)
Trial: 22951500
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus Vitamin D3 (1000 mg/d calcium plus 800 IU/d vitamin D3)
Trial: 16537378
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral N-acetylcysteine (0.6 to 1.0 g three times daily, for 4 weeks)
Trial: 16537378
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral N-acetylcysteine
Trial: 11130773
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg/day for 8 days)
Trial: 9058689
Drug: Inhaled heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled heparin (15,000 units USP/ml, 4 ml)
Trial: 7862817
Drug: Intravenous benztropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous benztropine (2 mg)
Trial: 4877600
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg)
Trial: 3732769
Drug: Chenodiol (chenodeoxycholate),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol (chenodeoxycholate), 750 mg/day
Trial: 3732769
Drug: Chenodiol (chenodeoxycholate),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodiol (chenodeoxycholate), 375 mg/day
Trial: 29779170
Drug: Oligofructose (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks)
Trial: 23258641
Drug: Transdermal electromotive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal electromotive administration of verapamil (10 mg) and dexamethasone (4 mg)
Trial: 23258641
Drug: Intra-lesional injection
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-lesional injection of verapamil (10 mg) and dexamethasone (4 mg)
Trial: 23258641
Drug: Transdermal electromotive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal electromotive administration of verapamil and dexamethasone
Trial: 21291509
Drug: Teams that
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teams that administered magnesium sulfate within the allocated time (10 minutes).
Trial: 15050862
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg and 2 mg on 2 successive days)
Trial: 9489052
Drug: Methadone doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone doses
Trial: 27071477
Drug: Experimental Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group (EG) - Four weeks of APA-focused training involving catching a medicine ball while standing
Trial: 24694794
Drug: AST-120 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (2 g 3 times daily for 8 weeks)